The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 935
Brown, L. M., & Olino, K. L. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2024.12.006 · Cited by 2
Treatment of Uveal Melanoma Using a Novel Radiosurgical Platform: A Case Report
Kinzl, S., Heussen, F. M., Kaiser, K. P., Hornberger, U., Becker, M. D., Mack, A., Weltz, D., Müller, M., Dettinger, B., Picardi, C., et al. (2025) · Cureus · doi:10.7759/cureus.81343 · Cited by 2
Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open
Joshi, U. M., Hundal, J., Mata, J. R., Schollenberger, M. D., Warrier, G., Luke, J. J., Lipson, E. J., & Funchain, P. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473856 · Cited by 2
Qi, X., Chen, G., & Cao, Y. J. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4558-1_20 · Cited by 2
Cellular Therapy for Advanced Melanoma
Zaemes, J. P., & Gibney, G. T. (2025) · Surgical Clinics of North America · doi:10.1016/j.suc.2025.03.004 · Cited by 2
Inì, C., Foti, P. V., Farina, R., Tiralongo, F., Castiglione, D., Cannarozzo, M., Spatola, C., David, E., Palmucci, S., Russo, A., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251343144 · Cited by 2
Lu, D., Chu, H.-Y., Park, S., Landon, M. B., Tsuda, M., Avramis, E. V., Dege, C., Dailey, T., Pan, Y., Hanok, S. K., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.030 · Cited by 2
Lubrano, S., Cervantes‐Villagrana, R. D., Arang, N., Officer, A., Adame-Garcia, S. R., Cuesta-Margolles, G., Aplin, A. E., & Gutkind, J. S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110712 · Cited by 2
Systemic Surveillance Guidelines for Uveal Melanoma: A Systematic Review
Zaman, F. Y., Ghaus, A., Shackleton, M. J., Kee, D., Joshua, A. M., O’Day, R., & Ameratunga, M. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70002 · Cited by 2
Self-citationBlood-Based Cell-Free DNA in Ophthalmic Oncology
Francis, J. H., & Abramson, D. H. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.10.7 · Cited by 2
The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
Ascierto, P. A., Warner, A. B., Blank, C. U., Caracò, C., Demaria, S., Gershenwald, J. E., Khushalani, N. I., Long, G. V., Luke, J. J., Mehnert, J. M., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03406-7 · Cited by 2
Self-citationApplication of Deep Learning Models in the Evaluation of Histopathology of Uveal Melanoma
Coupland, S. E., Zhang, H., Jones, H., & Zheng, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-08250-4_21 · Cited by 2
Population genetics and external proficiency testing for HLA disease associations
Mrázek, F. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1268705 · Cited by 2
Strategies and rules for tuning TCR-derived therapy
Mo, G., Lu, X., Wu, S., & Zhu, W. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.27 · Cited by 2
O’Day, R., Conway, R. M., Lim, L. S., Giblin, M., Cherepanoff, S., Joshua, A. M., McKay, D., McKenzie, J. D., Fog, L. S., Holly, P., et al. (2024) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2024.05.006 · Cited by 2
Self-citationWadt, K., Harbst, K., Sjøl, M. M. B., Rosengren, F., Yde, C. W., Rohrberg, K. S., Jensen, M. R., Heegaard, S., Kiilgaard, J. F., Gerdes, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306386 · Cited by 2
Gouda, M. A., Zarifa, A., Yang, Y., Stephen, B., Gurses, S. A., Sprenger, A., Tian, Y., Derbala, M. H., Oliva, I. G., Meric‐Bernstam, F., et al. (2025) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-10 · Cited by 2
Cell Death of Tumor Melanocytes and Treatment Options
Koval, O. A., Zhilnikova, M., Balantaeva, M., Biryukov, M., & Atamanov, V. V. (2025) · Biocell · doi:10.32604/biocell.2025.059987 · Cited by 2
Dermatological Toxicities of Tebentafusp, a New Bispecific Drug: Case Series and Literature Review
Mansilla‐Polo, M., de Unamuno‐Bustos, B., Martıń-Torregrosa, D., Martínez‐Cózar, V., Díaz‐Beveridge, R., & Estrada, R. B. (2025) · Australasian Journal of Dermatology · doi:10.1111/ajd.70004 · Cited by 2
Rôle du facteur de transcription HES6 dans le mélanome uvéal
Nucera, L., Perrée, E., Pujas, P., Rouchon, C., Wachich, M., Selveswaran, S., & Arrighi, N. (2022) · médecine/sciences · doi:10.1051/medsci/2022114 · Cited by 2
Bispecific Antibodies in Targeted Cancer Immunotherapy
Farhangnia, P., Delbandi, A., Sadri, M., & Akbarpour, M. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_189-1 · Cited by 2
Luo, S., Xie, C., Lin, N., Lin, D., Gu, D., Lin, S., Huang, X., Xu, X., & Weng, X. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000919 · Cited by 2
Tumor Lysis Syndrome Induced by Tebentafusp
Ruf, T., Leonhardt, A., Anz, D., Kunz, W. G., Röhrle, N., Foerster, P. I., Tomsitz, D., French, L. E., Seegräber, M., & Heinzerling, L. M. (2023) · Immunotherapy · doi:10.2217/imt-2023-0093 · Cited by 2
Giordano, G., & Pancione, M. (2023) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1631 · Cited by 2
Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review
Tran, D. H., Shanley, R. P., Giubellino, A., Tang, P. H., Koozekanani, D. D., Yuan, J., Dusenbery, K. E., & Domingo‐Musibay, E. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1406872 · Cited by 2
High C-Reactive Protein Levels Are Related to Better Survival in Patients with Uveal Melanoma
Meijer, N., de Bruyn, D. P., de Klein, A., Paridaens, D. A., Verdijk, R. M., Berendschot, T. T. J. M., Brosens, E., Jager, M. J., & Kılıç, E. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100117 · Cited by 2
Weninger, W. J. (2022) · hautnah · doi:10.1007/s12326-022-00501-w · Cited by 2
CADTH (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.628 · Cited by 1
Hassel, J. C., & Heppt, M. V. (2023) · Die Onkologie · doi:10.1007/s00761-023-01378-x · Cited by 1
Self-citationImmunotherapies for Cancer: Bi-specific T Cell Engagers (BiTEs)
Godby, R. C., Niu, A., & Paludo, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_3 · Cited by 1
Rosnev, S., Peuker, C. A., Piwonski, I., Ihlow, J., Leyvraz, S., Klingberg, J., Horst, D. A., Joosten, M., Möbs, M., Joussen, A. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115280 · Cited by 1
Self-citationUveal Melanoma: Adjuvant and Neoadjuvant Therapy
Khan, S. A., Yang, J., Singh, A. D., & Carvajal, R. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-81354-2_27 · Cited by 1
Self-citationNeue Therapieansätze in der neo-/adjuvanten Therapie des Melanoms
Zenderowski, V., Schreieder, L., Drexler, K., & Haferkamp, S. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05508-x · Cited by 1
Steinberg, H., Haubold, J., Bauer, S., Richly, H., Siveke, J. T., Wimmer, J., Umutlu, L., Schaarschmidt, B. M., Theysohn, J. M., & Ludwig, J. M. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.05.020 · Cited by 1
Lee, K.-J., Kim, G., Seo, B.-R., Jeong, S. Y., Kim, H. S., Cho, H. Y., & Park, S. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188941 · Cited by 1
Bispecific Antibodies in Targeted Cancer Immunotherapy
Farhangnia, P., Delbandi, A., Sadri, M., & Akbarpour, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_189 · Cited by 1
Recent advances in immunotherapy for breast cancer
Guo, Y. M., Zheng, G., Yu, F., Li, L., & Sun, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03493-0 · Cited by 1
Surgical Management of Pulmonary Metastases Secondary to Uveal Melanoma: A Case Series
Comanici, M., Robertus, J. L., Rice, A. J., Nathan, P., & Anikin, V. (2025) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2026.100918 · Cited by 1
Self-citationTüller, P., Kiefer, T., Jabbarli, L., Papaioannou, K., Schramm, K., Barwinski, N., Schönberger, S., Brecht, I. B., Schneider, D. T., Livingstone, E., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32147 · Cited by 1
Novel uveal Melanocyte cell lines display distinct features from uveal melanoma
Dalvin, L. A., Kopinski, P. K., Miley, D. R., Ong, H., Erickson, S. A., Andrews-Pfannkoch, C. M., Burr, S. D., & Armitage, J. A. (2025) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2025.11.005 · Cited by 1
Wefelnberg, M. M., Hennigfeld, S., Simon, M. S., Matos, P. W., Heindl, L. M., Rokohl, A. C., Bröckelmann, P. J., & Baumann, F. T. (2025) · Reports — Medical Cases Images and Videos · doi:10.3390/reports8040260 · Cited by 1
Uveal Melanoma: Changing Paradigms of Treatment
Piperno-Neumann, S. (2025) · Ocular Oncology and Pathology · doi:10.1159/000549994 · Cited by 1
Self-citationNanoengineered Bispecific Antibodies Mediate Cell to Cell Movement for Boosting Cancer Immunotherapy
Li, Y., Zhu, X., Wang, X., Zhao, G., Hu, M., Guo, Y., & Yang, W. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00094 · Cited by 1
Considerations on Interim Evaluation of OS in Pivotal Oncology Trials
Zhang, W., Ro, S. K., Zhao, J., Li, X., Jiang, Q., Sun, L., Marchenko, O., Lu, C. C., Liu, R., & on behalf of the Interim Evaluation of OS Workstream of the Statistical Methods in Oncology Scientific Working Group, B. S. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2606333 · Cited by 1
Hoang, T. A., Khan, S. M., & Sacher, A. (2026) · The Oncologist · doi:10.1093/oncolo/oyaf431 · Cited by 1
Ramtohul, T., Jasawant, X.-L., Sandoval, J. L., Mailly-Giacchetti, L., Pierron, G., Cassoux, N., Mariani, P., Stern, M., Renault, S., Rampanou, A., et al. (2026) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2026.02.009 · Cited by 1
Self-citationClinical Benefit and Global Regulation of Bispecific Antibody Drugs: A Cross-sectional Analysis
Wang, R., Zhu, T., & Huang, Y. (2026) · BioDrugs · doi:10.1007/s40259-026-00775-z · Cited by 1
Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations
Ahn, M., Szabados, B. E., Ince, W., Kim, J., Ku, B. M., & Keenan, B. P. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517508 · Cited by 1
Mutant-Selective T-cell Receptor Therapy for Solid Tumors
Parry, S. R., Jang, C., Leal, A., & Punekar, S. R. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0894 · Cited by 1
Dalvin, L. A., Burr, S. D., Miley, D. R., Ong, H., & Armitage, J. A. (2026) · Melanoma Research · doi:10.1097/cmr.0000000000001103 · Cited by 1
Woodard, G. E., Jardín, I., & Rosado, J. A. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118108 · Cited by 1
Choroidal Melanocytic Lesion Detection Using Patch Vectors With a Foundational Vision Transformer
Ye, R. Z., Leske, D. A., Mousavi, M. S., Iezzi, R., & Dalvin, L. A. (2026) · Translational Vision Science & Technology · doi:10.1167/tvst.15.6.1 · Cited by 1
The paradox of escalating immunotherapy for uveal melanoma liver metastases
Wong, P., Pollini, T., Hernandez, S., Tao, S., Qiao, G., Amouzegar, A., Bol, G. M., DAUD, A. I., Tao, D. L., Tsai, K. K., et al. (2026) · HPB · doi:10.1016/j.hpb.2026.05.010 · Cited by 1
Designing T-cell engagers: trade-offs between activity and safety
Zhang, Y., Wei, M., Shen, Y., Zhang, Z., He, Q., Yang, B., Cao, J., Zhao, W., Zhao, W., & Zhou, Z. (2026) · Protein & Cell · doi:10.1093/procel/pwag038 · Cited by 1
Abuhassan, Q., Saleh, K. A., Jyothi, S. R., Sahoo, R., Prakash, P., Mukherjee, G., Sinha, A., & Boyqulov, T. (2026) · Bioimpacts · doi:10.34172/bi.33219 · Cited by 1
Maloney, M. F., Caushi, J. X., Cullen, L. A., Andrews, A. R., Ford, A. C., Gizzi, A. S., Souza, C., Stokes, K. L., Dobrev, V. S., Krapfl, K., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-1252 · Cited by 1
Treatment of Metastatic Uveal Melanoma. The Experience of a Leading Reference Center
Nazarova, V. V., Магомедова, З. Р., Орлова, К. В., Азарова, Е. А., Unguryan, V. M., Utyashev, I. A., Романов, Д. С., Markina, I. G., Самойленко, И. В., Kharkevich, G. Y., et al. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-5-74-79 · Cited by 1
Enhancing the utility of chromosome 6 and 8 testing in uveal melanoma biopsies
Matušková, V., Horňáčková, P., Michalec, M., Zlámalíková, L., Matulova, K., & Uher, M. (2024) · Biomedical Papers · doi:10.5507/bp.2024.018 · Cited by 1
Piperno-Neumann, S., de Koning, L., Marchal, T., Gastaud, L., Waechter, L., Fogliarini, A., Bouleuc, C., Libert, Y., Seban, R., Marret, L., et al. (2024) · Melanoma Management · doi:10.1080/20450885.2024.2382080 · Cited by 1
Self-citationBewarder, M., Christofyllakis, K., Petersen, M., Held, G., Smola, S., Carbon, G., Bette, B., Link, A., Kiefer, M., Bittenbring, J. T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312908 · Cited by 1
Hueso, T., Cagnat, J., Ouali, K., Haberstich, M., Henry, B., Danu, A., Bigenwald, C., Merad-Boudia, M., Messayke, S., Laparra, A., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf164 · Cited by 1
Data-Driven Visualization of the Dynamics of Antimicrobial Peptides in Cell Death
Hou, D., Zhao, J., Guo, M., Zhang, X., Yu, S., Li, J., Forouzanfar, T., Zhang, Q., & Pathak, J. L. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10578-3 · Cited by 1
Whittle, J. R., Vieito, M., Rohrberg, K. S., Rodriguez-Ruiz, M. E., Álvarez, E. C., Mellinghoff, I. K., van Linde, M., Cloughesy, T. F., Reardon, D. A., Chong, R. A., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf160 · Cited by 1
Wang, X. M., Furness, A. J. S., & Heelan, K. (2025) · Clinical and Experimental Dermatology · doi:10.1093/ced/llaf426 · Cited by 1
Panagiotidis, K., Owens, S. L., Finegan, G., Horgan, N., Tsavdaridis, S., Kennedy, S., & Floudas, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04198-7 · Cited by 1
Smarsly, D., Kreuzberg, N., Langhorst, C., Scheffler, M., Siebolts, U., Lennartz, S., Koll, P., Glaser, A.-C., & Franklin, C. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105921 · Cited by 1
Ön, S., Cebeci, S., Turna, H., SEVGEN, Z. G. G., Güven, D. C., Kılıçkap, S., Başer, M. N., Demir, B., Biter, S., Bayram, E., et al. (2026) · Cancers · doi:10.3390/cancers18030394 · Cited by 1
De novo identification of the specificities of recurrently identified human T cell receptors
Kasbe, M., Yahsi, B., Whitehead, K. D., Oh, J., Mosharraf, M., Sohn, K., Phan, T., & Lee, M. N. (2026) · Science Advances · doi:10.1126/sciadv.aeb1732 · Cited by 3
The complement system contributes to the immunosuppressive microenvironment of uveal melanoma
Zherka, I., Kalirai, H., Majorova, D., Coupland, S. E., & Olcina, M. M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07910-y · Cited by 1
Jafry, R., Qamar, S. B., Irfan, S., Abid, M. A., Mohlere, V., Maithel, N., Jafri, S. H., Awasthi, S., Srour, S. A., Vaziri, I., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04802-x · Cited by 1
Cognitive dysfunction associated with cellular immunotherapy for cancer
Hauswirth, A. G., Parsons, M. W., & Dietrich, J. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag021 · Cited by 1
Nelson, A., Riise, R. E., Alsén, S., Wong, A., Carlson, P., Edman, S., Holgersson, J., Bagge, R. O., Johansson, I., Sadik, M., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014401 · Cited by 1
Simmonds, F. C., Kashua, V., McDonnell, D. E., El-Ashmawy, M., & Coromilas, A. J. (2026) · Dermatology Reports · doi:10.4081/dr.2026.10366 · Cited by 1
Smart, K., Rodriguez, I., Swanson, M. S., Berry, J. L., Terando, A. M., Peng, D., Worswick, S., & In, G. K. (2026) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70089 · Cited by 1
Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells
Zi, G., Zhang, L., Zhou, L., Liu, X., Wang, L., Zhou, R., Zheng, P., Wei, J., Chen, X., & Wei, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02780-8 · Cited by 1
Cancer immunotherapy: Current progress and future perspectives
Alu, A., Zhou, Y., Battaglia, G., Wei, Y., & Wei, X. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100031 · Cited by 1
Lazzaro, S., Leroux-Roels, G. G., Janetzki, S., Salaun, B., Cook, L. E., Franke, K., Poschke, I. C., Bunse, L., Welters, M. J. P., Fehlings, M., et al. (2026) · Nature Protocols · doi:10.1038/s41596-026-01453-8 · Cited by 1
Tebentafusp desensitization in an adult with metastatic uveal melanoma
Herrera, E., Pappano, E., Fayngor, R. A., Hahn, E., Pappalardo, A. A., Naffakh, N., Hinkes, J., & Nguyen, R. H.-T. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261495131 · Cited by 1
Hassel, J. C., & Berking, C. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14740_g · Cited by 1
Self-citationImmunotherapy for the treatment of metastatic uveal melanoma
Podhorec, J., Lakomý, R., Poprach, A., & Kišš, I. (2022) · Onkologie · doi:10.36290/xon.2022.026 · Cited by 1
Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not Yet
Abraham, I. L., Calamia, M., & MacDonald, K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4226 · Cited by 1
Advanced melanoma—A curable disease? Implications of systemic treatment on patients' daily life
Thoms, K. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19018 · Cited by 1
Perez, M. C., DePalo, D. K., & Zager, J. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2245333 · Cited by 2
Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer
Borgeaud, M., Friedlaender, A., & Addeo, A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-466 · Cited by 1
Geidel, G., Abeck, F., Hansen, I., Kött, J., Heidrich, I., Rünger, A., Hildebrandt, L., & Gebhardt, C. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19660 · Cited by 1
ASO Author Reflections: Percutaneous Hepatic Perfusion: Past, Present, and Future
Zager, J. S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15364-z · Cited by 1
Immunotherapy for Ocular Malignancies
Alijanzadeh, D., Ghazizadeh, Y., Akbarzadeh, D., Jolfayi, A. G., Irilouzadian, R., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_242 · Cited by 1
Lischer, C., Eberhardt, M., Flamann, C., Berges, J., Güse, E., Wessely, A., Weich, A., Retzlaff, J., Dörrie, J., Schaft, N., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008104 · Cited by 1
Nebenwirkungen dermatoonkologischer Therapien
Hassel, J. C., & Zimmer, L. (2024) · Die Dermatologie · doi:10.1007/s00105-024-05354-3 · Cited by 1
Self-citationFrontiers and challenges of immune cell therapy research in solid tumors
Xing, X., Wang, Z., Wu, M. P., & Yao, G. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0428 · Cited by 1
Kudelka, M. R., Richards, A. L., Friedlander, P. A., Wolchok, J. D., Moy, A. P., & Shoushtari, A. N. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009609 · Cited by 1
Self-citationToumi, E., Hesson, L. B., Lin, V. Y., Wright, D. C., Hajdu, E., Lim, L. S., Giblin, M., Zhou, F., Hoffmeister, A., Zabih, F., et al. (2024) · Cancers · doi:10.3390/cancers16244152 · Cited by 1
Bispezifische Antikörper in der Therapie hämatologischer Neoplasien und solider Tumoren
Zhou, X., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-025-01695-3 · Cited by 1
Diagnostic Techniques: Other Biopsy Techniques
Damato, B. E., Afshar, A. R., Hussain, R. N., Heimann, H., Groenewald, C., & Coupland, S. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-75907-9_25 · Cited by 1
Principles and Complications of Chemotherapy
Zahler, S. G., Ghazi, N. G., & Singh, A. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-75907-9_15 · Cited by 1
Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint Inhibitors
Shao, Y. F., Baca, Y., Hinton, A. C., Xiu, J., Vanderwalde, A. M., Hadfield, M. J., Park, S. J., Darabi, S., Sato, T., & Moser, J. C. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000558 · Cited by 1
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma
Ryan, V. V., Zahrieh, D. M., Strand, C. A., Churchill, R., Dalvin, L. A., & Dudek, A. Z. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001042 · Cited by 1
Validation of Four Prognostic Models for Metastatic Posterior Uveal Melanoma in a Danish Cohort
Hindsø, T. G., Bjerrum, C. W., Nissen, K., Bagger, M. M., Faber, C., Heegaard, S., Madsen, K., Rosthøj, S., & Kiilgaard, J. F. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.38 · Cited by 1
Quels traitements pour le mélanome uvéal ?
Papasotiriou, E. C., Chessel, E., Costa, C., Daniel, L., Deridder, I., Garyga, S., Gineste, C., & Nahon‐Estève, S. (2022) · médecine/sciences · doi:10.1051/medsci/2022112 · Cited by 1
Treatment of metastatic uveal melanoma
Polaczek, M. M., & Koseła-Paterczyk, H. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0057 · Cited by 1
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
